The diaminodithiol (DADT) ligand has been conjugated to the neuromuscular blocking agent benzovesamicol (BVM) in the 5-position. DADT-BVM 1 was synthesized by coupling of 5-aminomethylbenzovesamicol with a BCA thiolactone reagent. %Tc radiolabeling of 1 with PgmTclglucoheptonate gave a 4.7: 1 mixture of two %Tc complexes as determined by HPLC. Biodistribution data of the major [gRnTc]-I complex in CD-l mice (n = 4-5) showed very little uptake and no regional selectivity in the mouse brain. At all time points examined, the lung and liver showed the highest uptake. For whole brain, the % injected dose values were 0.27, 0.12, 0.04 and 0.01% at t = 1, 5, 30 and 240 min. The major p"Tc]-1 product exhibited a log P = 3.13 + 0.06 (SD) with an IC,, = 140-280 nM for the corresponding $Tc]-1 vs ( -)-N-[3H]methyl-5-aminobenzovesamicol. The low brain uptake of [99mTc]-1 vs 5-iodobenzovesamicol is attributed to its higher molecular weight (752) and lower binding affinity.
Introduction 5- ['25"231] Iodobenzovesamicol (Scheme 1, X = I) is a stereospecific radiotracer for mapping cholinergic neurons in the brain (Jung et al., 1990 (Jung et al., , 1993 (Jung et al., , 1994 . ( -)-2R, 3R-5-['231] Iodobenzovesamicol is undergoing clinical trials as a potential SPECT clinical agent for the study of Alzheimer's disease . A structural study of benzovesamicol (BVM) derivatives by Rogers et al. (1989) showed that substitution of a variety of large functional groups, including biotin, in the 5-position of BVM had little effect on in vitro potency. In vivo studies of the neuronal mapping potential of a series of iodobenzovesamicols have revealed that considerable bulk tolerance exists in positions 5, 6 and 7 of BVM (Jung et al., 1990 (Jung et al., , 1993 (Jung et al., , 1994 .
These observations led to the hypothesis that a technetium-99m chelate group might be introduced in the 5-position of BVM without adversely affecting its in vivo neuronal mapping characteristics (Scheme 2, [99mTc]-1). The chief advantages of a 99"Tc-radiolabeled BVM are that it: (1) permits the use of the more readily accessible and inexpensive 99mTc and (2) allows the possible development of a convenient "kit" *All correspondence should be addressed to: Dr Renato B.
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formulation. In this paper, we describe the synthesis of the first diaminedithiol (DADT) conjugate of BVM and a preliminary evaluation of its in vivo properties.
Experimental (&)-tram-5-Cyano-2-hydroxy-3-(4_phenylpiperi-dine)-tetralin(5-cyanobenzovesamicol)
To a cooled (xS'C) heterogeneous solution of ( + )-5-aminobenzovesamicol (0.5 g, 1.55 mmol) (Rogers et al., 1989) (Scheme 1, X = NH,) in concentrated HCI (3 mL) and water (10 mL) was added dropwise a cooled solution of sodium nitrite (114 mg, 1.64 mmol) in water (5 mL). The reaction temperature of the resulting clear yellow solution was maintained below 10°C. The diazonium salt was neutralized with sodium carbonate and added to a solution (=5OC) of nickel chloride (502 mg, 3.88 mmol) and potassium cyanide (808 mg, 12.40mmol) in 20mL water. The reaction mixture was stirred for 1 h, allowed to warm to room temperature and stirred for an additional 3 h. The mixture was then gently warmed on a water bath (2 h) and the ensuing brown precipitate was filtered off. The brown precipitate was refluxed for 3 h with ethylene diamine (1 mL) and KCN (1 .O g) 
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To a 5 mL vial equipped with a micro stir bar containing 56.6 mg (0.18 mmol) of 5-methylaminobenzovesamicol was added a solution of the BCA thiolactone compound (Baidoo and Lever, 1990a) (184.4mg, 0.50mmol) in 6OOpL acetonitrile. The slurry became a homogeneous light pink-orange clear solution and the mixture was stirred at room temperature. The reaction was monitored by TLC [silica, ethyl acetate/hexane (1: l)]. The desired DADT-BVM conjugate was visualized with bromocresol green and appeared as a streak near the origin. (Excess thiolactone appeared at R, > 0.5.) After 3 h the reaction mixture was purified directly by flash chromatography on silica (13.0 g, K60, 230 mesh, 0.063 mm, EM Sciences) using ethyl acetate/hexane (1: 1) as eluent. After elution of the excess thiolactone, the desired DADT-BVM fractions were pooled, rotoevaporated to an oil and dried overnight in uacuo to yield 1 as a waxy solid [(64.2 mg, 58%), 'H-NMR (CDCl,, 300 MHz): 6 1.06 (s, 6H) 1.28 (s, Synthesis and evaluation of a wm'99Tc-DADT-benzovesamicol b / \ -6H), 1.38 (s, 6H), 1.55-2.00 (br, CH,, S-H, N-H and @H, 8H), 2.74 (s, 2H), 2.63 (s, 2H), 2. (De Kieviet, 1981) . Impure NH,TcO,/TcO, (1.9 mCi, 0.20 g) (NEN, Billerica, Mass.) was first purified according to the method of Deutsch (Stepniak-Biniakiewicz et al., 1992). The resulting white NH,TcO, residue (2.0 mmol 99Tc) was dissolved in an aqueous solution (50.0 mL) of SnCl, (Aldrich, St Louis, MO.) (219 mg, 1.16 mmol) and D-glycero-D-gulo-heptonic acid, sodium salt dihydrate (Aldrich, St Louis, MO.) (8.10 g, 28.5 mmol). For radiolabeling, 1.9 mg (2.7pmol) of 1 (oxalate salt) in 1.0 mL water/ethanol (1: I) was treated with 7OpL of the P'Tclglucoheptonate solution. Shortly after addition of the deep purple [99Tc]glucoheptonate, the solution turned goldenbrown. The 99Tc-radiolabeled products were isolated by HPLC as described above and co-eluted with the corresponding [99mTc]-1 complexes. After several injections, the combined golden yellow HPLC fractions containing the major P9Tc]-1 product were rotoevaporated to near dryness and the ensuing fine golden yellow precipitate ( w 2 PCi) was carefully collected by gravity filtration through a glass pipet containing a plug of glass wool. The precipitate was dissolved in a minimum amount of ethanol, degassed and stored at -70°C under argon.
Determination of log P
The log P of the major [99mTc]-1 product was determined by an analogous procedure used for [99"Tc]-p-iodophenethyldiaminodithiol (Shiba et al., 1992). Fifty (50) PCi of [99"Tc]-1 was added to 3.5 mL 0.1 M phosphate buffer @H = 7) and 3.5 mL l-octanol. The mixture was inverted 60 times and centrifuged for 20min. A sample of the octanol (lO-2OpL) and buffer (lOO-2OOpL) layers was assayed on a Packard Minaxi 5000 y-counter. Log P was calculated from the octanol/buffer cpm ratio. The major portion of the octanol layer (3.0 mL) was diluted with 0.5 mL octanol and mixed with a fresh portion of 3.5 mL phosphate buffer. The equilibration procedure described above was repeated until a constant value of log P was obtained. From six equilibrations, the log P of the major [99mTc]-1 product was determined to be 3.13 _+ 0.06 (SD).
IC, determination
The IC5,, was measured using a modified competitive binding assay (Bennett, 1978) employing ( -)-N-['HImethyl-5-aminobenzovesamicol (Jung et al., 1993 (Jung et al., , 1994 and [99Tc]-1. The assays were performed by incubating tritiated compound, P9Tc]-1 (> 98% pure by HPLC), cortex homogenate extract (2 pg protein/pL) and buffer for 1 h at 37°C (total incubation volume = 500 pL). The protein bound activity was isolated on Whatman GF/B filters (Brandel Inc., Gaithersberg, Md) using a Brandel IP-48LT Cell Harvester. After washing, the filters were cut out and mixed with scintillation fluid. The decrease of 3H bound activity and corresponding increase in 99Tc activity as a function of P9Tc]-1 concentration were measured using a Packard Tri-carb 4530 scintillation counter using the appropriate channels (O-19 for 'H and 2&292 MeV for 99Tc).
Animal studies
Radiotracer was formulated for animal injection by a g-fold dilution of the HPLC purified product with physiologic saline. Female CD-l mice (2&30 g) were anesthesized (ether), administered 10-20 pCi via i.v. tail vein injection of the above formulation. The mice were sacrificed at 1, 5, 30 and 240 min, respectively and the tissues harvested and counted on a Packard Minaxi 5000 y-counter. Biodistribution data in the brain and peripheral tissues are given in Tables 1 and 2 .
The blood activity contribution to the brain tissues (Table 1) was estimated based on whole body and regional brain blood volume literature data for the rat (Lee and Blaufox, 1985; Cremer and Seville, 1983) . The whole body blood volume has been determined to be only x4.5+.3% (Lee and Blaufox, 1985) . The regional blood volumes for cortex, cerebellum, hypothalamus and hippocampus ranged from 7.1 to 10.89~L/lOOOmg brain tissue (Cremer and Seville, 1983). Using these values, the blood Synthesis and evaluation of a Wm'99Tc-DADT-henzovesamicol contribution was estimated as follows: with the cerebellum as an example, the amount of blood in 71 mg (mean weight) of cerebellum was calculated to be ~0.773 pL. From Table 2 (t = 1 min), the blood activity contribution in the cerebellum is therefore 0.773 PL x 103~g/~L x 28.7% ID/106pg ~0.022% ID or z 0.3 1% ID/g cerebellum :;.022% ID/O.071 g cerebellum). The blood activity contribution in the cerebellum is therefore 0.31/0.69 (Table 1) or ~45% of the total cerebellum activity at 1 min. For other brain sections the blood activity was calculated as: %ID (blood, brain tissue)/g brain tissue z blood volume (pL mg-') x % ID/g blood (at time t ) assuming a blood density of 1 w/p L.
Results and Discussion
There are only very few published reports of potential %Tc brain receptor mapping reagents. The feasibility of in vitro and in vivo receptor mediated targeting using small organic molecules labeled with 99mT~ has been demonstrated unequivocally by Katzenellenbogen and Davison (DiZio et al., 1991, 1992) . They published the first detailed study of Re and Tc DADT progestin receptor agents which exhibited high binding affinity to a number of steroid receptors. Lever and co-workers (Lever and Wagner, 1990; Lever et al., 1994) have prepared a [99mTc]-DADT conjugate of quinuclidinyl benzylate (QNB). Receptor binding studies indicated that the affinity of the complex for the muscarinic receptor was in the micromolar range as compared to the nanomolar affinity of QNB itself. A group at Squibb has also prepared a number of QNB-BAT0 conjugates suitable for WmTc labeling (Nanjappan et al., 1993) . Realizing that modification of spiperone at the amide position with large substituents resulted in retention of high affinity for the dopamine D-2 receptor, Ballinger and co-workers prepared a 99mTc dithiocarbamate conjugate (Ballinger et al., 1989) . However neither the ligand precursor nor the 99mT~ complex was structurally characterized. The 99mTc-radiolabeled product had limited stability and showed negligible brain uptake in vivo. In the course of our studies with [ L25i'231]iodobenzovesamicols (Jung et al., 1990 (Jung et al., , 1993 (Jung et al., , 1994 Kuhl et al., 1993) , it became evident that the precursor, 5-aminobenzovesamicol (Rogers et al., 1989) , could easily be functionalized to include a benzylic amine for conjugation to a 99m199Tc-DADT chelate.
The 99m'99T~ ligand DADT-BVM 1 was synthesized by coupling of 5-aminomethylbenzovesamicol (Scheme 1) with the previously reported BCA thiolactone reagent (Baidoo and Lever, 1990a ) (Scheme 2). 5-Aminomethylbenzovesamicol was prepared in two steps by cyanation of 5-aminobenzovesamicol (Rogers et al., 1989) followed by reduction with lithium aluminum hydride (Scheme 1). The analytical data for 1 confirms its structure as a 1:l adduct analogous to that obtained from the reaction of the BCA thiolactone reagent with benzylamine (Baidoo and Lever, 1990b) . The 300 'H-NMR spectrum of 1 is characterized by resonances at 7.97ppm (amide proton), a doublet (two protons) at 4.48 ppm (Ar-(X,-NH-) and a singlet (2 protons) at 3.49 ppm [-CO-CH,-N(CH,)-] in addition to those for the parent BVM and thiolactone precursors. The chemical shift assignments of the two methylene protons are in close agreement with values predicted by Shoolery's rules (Gordon and Ford, 1972) and those of a DADT-benzylamine conjugate (Baidoo and Lever, 1990b) . The S-H and N-H resonances appear as a broad overlap at z 1.8 ppm as has been typically observed for a number of DADT-conjugates (DiZio et al., 1991; Shiba et al., 1991 Shiba et al., , 1992 . 99mi99T~ radiolabeling of 1 (Scheme 2) with 99"'99Tc-glucoheptonate proceeded smoothly to give two [99m'99Tc]-1 complexes (ratio = 4.7/l for WmT~ and 3.3/l for 99Tc). As depicted in Scheme 2, the production of two 99m'99T~ products is consistent with the expected formation of syn and anti diastereomeric complexes arising from the two possible orientations of the N-substituent with respect to the Tc(=O)N,S, plane. In earlier work by Lever and co-workers on a number of N-substituted DADT technetium complexes, the structures of the major and minor product(s) were assigned as the syn and anti isomers, respectively (Lever et al., 1985 (Lever et al., , 1990 Lever and Wagner, 1991) . In the case of the N-ethylpiperidinyl-DADT complexes, it was also found that the major (svn) product exhibited better brain uptake (Lever et al., 1985) .
In view of these previous findings, its higher yield and easier purification, the predominant ~9mi99T~]-1 peak (R, = 55 min) was chosen for all subsequent preliminary in vitro and in vivo screening described below. HPLC analysis of the HPLC purified major [99mT~]-1 complex revealed no degradation throughout the duration of the animal experiments. Cumulative biodistribution data for pmTc]-1 in CD-l mice (n = 4-5) after 1, 5, 30 and 240 min post-injection are Table 2 . &take (% dose/e + SD) of 199"Tcl-1 in Derinheral tissues % Dose/g 1 min (n = 4) 5 min (n = 4) 30 min (n = 4) 240 min (n = 5) given in Tables 1 and 2 . At all time. points examined, the lung and liver showed the highest uptake (Table 2) . Table 1 shows that P'"Tc]-1 is rapidly cleared from the brain within 4 h. For whole brain, the % ID values were 0.27, 0.12, 0.04 and 0.01% at t = 1, 5, 30 and 240 min. In contrast to the biodistribution of 5-iodobenzovesamicol (Jung et al., 1990) , no regional selectivity was observed in the striatum, cortex and cerebellum as well as in the heart at all time points examined (Tables 1 and 2 ). Interpretation of the low brain uptake (Table 1) is further complicated by the corresponding high activities in the blood ( Table 2) . The blood activity contributions in the brain tissues were calculated to be significantly high, particularly at t = 1 and 5 min. The blood activity contribution was estimated using regional brain blood volume data for the rat (Cremer and Seville, 1983 ) and the observed blood activity data ( Table 2) . The blood activity contributions in the cortex, cerebellum, hypothalamus and hippocampus were calculated to be 42-57% at 1 min and 294% at 5 min of the values reported in Table 1 . At later time points, the contributions were significantly lower (8-19 and 4-16% at 30 and 240min, respectively). Two principal factors could account for the observed low brain uptake. First, the relatively high molecular weight (752) and larger size of the [99mTc]-1 complex may have substantially reduced brain permeability. A study by Levin (1980) proposed that an upper limit of 657 exists for crossing the blood-brain barrier. Although other compounds heavier than 657 have shown reasonable brain uptake, these data provided a qualitative limit of x600 for most technetium complexes synthesized to date (Nowotnik, 1992) .
The measured log P of the major [99mTc]-1 product (3.13) is slightly lower than that of 5-iodobenzovesamicol (3.37) (Jung et al., 1993 (Jung et al., , 1994 . This suggests that the complex is sufficiently lipophilic to cross the BBB. The IC,, of the corresponding (+)-99Tc-1 (> 98% pure by HPLC) was measured using a modified competitive binding assay (Bennett, 1978) employing ( -)-N-[3H]methyl-5-aminobenzovesamico1 (Jung et al., 1993 (Jung et al., , 1994 . Over a concentration range of < 1 PM in ( & )-99Tc-1, a decrease in ( -)-N-[3H]methyl-5-aminobenzovesamicol binding was observed, accompanied by a corresponding increase in ( f )-99Tc-1 bound activity. The ICso of ( + )-9gTc-1 (140-280 nM) was found to be significantly higher than that of ( + )-5-iodobenzovesamicol (ICso = 2 nM). The low brain uptake of p9"Tc]-1 is likely due to its large mass; its lack of regional brain selectivity may be attributed to its reduced affinity for the vesamicol binding site.
Conclusion
We have successfully prepared the first DADT-BVM conjugate 1 and have labeled it with 99m'99Tc. Although the major 99mT~-1 product showed a lipophilicity similar to that of 5-iodobenzovesamicol, very little uptake and no regional selectivity was observed in the mouse brain. Considered together, the in vitro and in uivo data for 99m'9gT~-1 suggest that its low uptake and retention in the brain are probably due to a combination of both increased size and reduced binding affinity. These initial results not only demonstrate that BVM can be labeled with 99mT~, but that labeling can be accomplished without (a) greatly modifying the lipophilicity of the parent molecule or (b) loss of binding ability. Although the I& of [99mi9!'Tc]-1 approaches the micromolar range, the binding data is encouraging and suggests that further improvements could be made by reduction of the chelate size (O'Neil et al., 1993). These findings help define the limitations imposed on the design of a 99mTc labeled vesamicol analogs for in uivo cholinergic nerve mapping. Future efforts will be guided by these constraints.
